Imaging biomarkers for cardiometabolic risk stratification in metabolic dysfunction-associated steatotic liver disease: incremental value of coronary artery calcification, epicardial adipose tissue, controlled attenuation parameter, and liver stiffness measurement beyond clinical scores
British Journal of Radiology · 01.10.2026 · 99 (1186) · 2035-2053
DOI: 10.1093/bjr/tqag112 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Radiology, online erschienen am 15.05.2026. Verfasst von Jiaxin Zhong und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Educ…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Fatty Liver, Non-alcoholic Fatty Liver Disease, Vascular Calcification. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Postdoctoral Fellowship Program of CPSF.
Abstract (Originalsprache)
Objectives
To systematically synthesize evidence on the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and imaging biomarkers of subclinical atherosclerosis and hepatic steatosis/fibrosis, and to quantify the magnitude of these associations across study populations.
Methods
We systematically searched PubMed, Embase, Web of Science Core Collection, and Cochrane Library (January 2000-February 28, 2026) for observational studies enrolling adults with MASLD (or historical NAFLD/MAFLD) that reported atherosclerotic cardiovascular disease (ASCVD)-related imaging outcomes. Primary outcomes were continuous coronary artery calcium (CAC; Agatston units), epicardial adipose tissue (EAT; cm3), controlled attenuation parameter (CAP; dB/m), and liver stiffness measurement (LSM; kPa). Weighted mean differences (WMDs) for continuous outcomes and odds ratios (ORs) for dichotomized thresholds were pooled using random-effects models with restricted maximum likelihood (REML) estimation and Hartung-Knapp adjustment where applicable; heterogeneity was quantified with I2 and τ2.
Results
Sixteen observational studies (n = 34 713; 6 cohorts, 10 cross-sectional) from North America, Asia, and Europe were included. In modality-specific threshold analyses, MASLD was associated with higher odds of subclinical disease: CAC (OR 1.41, 95% CI: 1.32-1.51; I2 = 75.0%), high EAT (OR 1.44, 95% CI: 1.21-1.68; I2 = 0%), high CAP (OR 1.47, 95% CI: 1.35-1.58; I2 = 0%), and high LSM (OR 1.49, 95% CI: 1.31-1.66; I2 = 0%). For continuous outcomes, CAC was higher by 49.2 Agatston units (95% CI: 46.8-51.7; I2 = 75.4%) and LSM was higher by 0.57 kPa (95% CI: 0.46-0.68; I2 = 0%) in MASLD versus comparators. EAT (k = 2; n = 4306): WMD 76.18 cm³ (95% CI: 5.04-147.32; I2 = 98.3%) (exploratory only; not suitable for point estimation). CAP (k = 2; n = 6652): WMD 45.12 dB/m (95% CI: 0.96-89.27; I2 = 98.1%) (exploratory only; not suitable for point estimation).
Conclusions
MASLD is consistently associated with greater calcific coronary burden, pericoronary adiposity, hepatic steatosis, and hepatic stiffness relative to non-MASLD comparators. These findings represent between-group imaging differences and should be interpreted as evidence of concurrent adverse imaging burden rather than formal demonstration of incremental predictive value beyond validated clinical risk engines. Whether these biomarkers improve discrimination, reclassification, or net clinical benefit beyond established scores (Pooled Cohort Equations [PCE], SCORE2, Framingham Risk Score [FRS]) requires prospective validation with pre-specified incremental prediction analyses. Advances in knowledge This study provides a comprehensive quantitative, multimodality synthesis demonstrating that MASLD is consistently associated with concurrent adverse changes across 4 key imaging biomarkers spanning subclinical atherosclerosis (CAC, EAT) and hepatic disease burden (CAP, LSM), establishing a critical evidence base to motivate prospective studies on integrating standardized imaging protocols to refine ASCVD risk characterization in MASLD populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xian…
- Department of Kidney Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, 410011, China.
Förderung
- Postdoctoral Fellowship Program of CPSF
Zitieren
APA
Zhong, J., He, H., Zhao, Y., Zeng, J., & Cai, Z. (2026). Imaging biomarkers for cardiometabolic risk stratification in metabolic dysfunction-associated steatotic liver disease: incremental value of coronary artery calcification, epicardial adipose tissue, controlled attenuation parameter, and liver stiffness measurement beyond clinical scores. British Journal of Radiology, 99(1186), 2035-2053. https://doi.org/10.1093/bjr/tqag112
Vancouver
Zhong J, He H, Zhao Y, Zeng J, Cai Z. Imaging biomarkers for cardiometabolic risk stratification in metabolic dysfunction-associated steatotic liver disease: incremental value of coronary artery calcification, epicardial adipose tissue, controlled attenuation parameter, and liver stiffness measurement beyond clinical scores. British Journal of Radiology. 2026;99(1186):2035-2053. doi:10.1093/bjr/tqag112
BibTeX
@article{Zhong2026,
author = {Zhong, Jiaxin and He, Huifen and Zhao, Yiwei and Zeng, Jiao and Cai, Zixin},
title = {Imaging biomarkers for cardiometabolic risk stratification in metabolic dysfunction-associated steatotic liver disease: incremental value of coronary artery calcification, epicardial adipose tissue, controlled attenuation parameter, and liver stiffness measurement beyond clinical scores},
journal = {British Journal of Radiology},
year = {2026},
volume = {99},
number = {1186},
pages = {2035--2053},
doi = {10.1093/bjr/tqag112}
}
EUVIMED